Global burden of MAFLD, MAFLD related cirrhosis and MASH related liver cancer from 1990 to 2021

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Фев. 27, 2025

Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most prevalent chronic globally, driven by rising obesity, metabolic syndrome (MetS), and type 2 diabetes mellitus (T2DM). This study evaluates global, regional, national burden of MAFLD-related diseases from 1990 to 2021 projects future trends. Data were sourced Global Burden Disease (GBD) database, including estimates for incidence, prevalence, mortality, disability-adjusted life years (DALYs) associated with MAFLD, cirrhosis, MASH-related cancer. Countries classified into 21 regions five socio-demographic index (SDI) quintiles analyze health disparities. Decomposition analyses assessed contributions population growth, aging, epidemiological shifts. Future trends modeled using Bayesian Age-Period-Cohort (BAPC) framework. In 2021, approximately 1.27 billion MAFLD cases reported an age-standardized prevalence rate (ASPR) 15,018 per 100,000. The highest incidence occurred in South East Asia. Mortality reached 138,328 97,403 cirrhosis. highlighted growth aging as key drivers. BAPC projections indicate a continued rise burden, particularly low- middle-income countries. underscores increasing global its complications. Targeted public interventions focusing on prevention early management are urgently needed mitigate impacts.

Язык: Английский

---

Dual etiology vs. MetALD: how MAFLD and MASLD address liver diseases coexistence

Metabolism and Target Organ Damage, Год журнала: 2025, Номер 5(1)

Опубликована: Март 27, 2025

Fatty liver disease associated with metabolic dysfunction has emerged as a significant global health challenge. This condition often coexists other diseases, such alcohol-related and viral hepatitis, complicating both diagnosis management. To address the limitations of non-alcoholic fatty (NAFLD) classification, two alternative frameworks have been proposed: dysfunction-associated (MAFLD) in 2020 steatotic (MASLD) 2023. A key difference between these definitions is how they consider relation to coexistence conditions. MAFLD adopts dual etiology concept, creating unified classification system that aligns contemporary clinical epidemiological needs. In contrast, MASLD introduces new term, MetALD (metabolic alcohol-related/associated disease), describe patients who excessive alcohol intake. review critically examines clinical, research, implications differing approaches MASLD, offering insights into their potential enhance understanding management multi-etiology diseases.

Язык: Английский

---

Letter: Comparison of the Efficacy of Adjuvant PD‐1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Related HCC Versus Other Aetiologies

Alimentary Pharmacology & Therapeutics, Год журнала: 2025, Номер unknown

Опубликована: Апрель 4, 2025

Язык: Английский

---

What is new in the 2024 Chinese guidelines for fatty liver disease?

Clinical and Molecular Hepatology, Год журнала: 2025, Номер unknown

Опубликована: Янв. 21, 2025

Язык: Английский

---

The “Chinese Approach” Towards Diagnosis and Management of Fatty Liver Diseases: Seek Common Ground While Reserving Differences

Journal of Digestive Diseases, Год журнала: 2025, Номер unknown

Опубликована: Янв. 26, 2025

Jian Gao Fan is an Editorial Board Member for the Journal of Digestive Diseases and was not involved in editorial review or decision to publish this article. All authors declare that there are no competing interests.

Язык: Английский

---

Thioredoxin-interacting protein TXNIP as a promising diagnostic marker for metabolic-associated fatty liver disease in patients with type 2 diabetes

Meditsinskiy sovet = Medical Council, Год журнала: 2025, Номер 23, С. 137 - 143

Опубликована: Янв. 22, 2025

Introduction . Metabolic-associated fatty liver disease (MAFLD) is a common that has pathogenesis-based relationship with type 2 diabetes (T2D). Aim. To determine the levels of TXNIP protein in patients MAFLD and T2D who were on metformin monotherapy, to compare these findings MRI liver, assess changes six months after starting treatment glucagon-like peptide-1 receptor agonists (GLP-1RA) sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Materials methods The study included 49 (34 female 15 male) MAFLD, aged 55 ± 8 years, followed up at outpatient clinic Almazov National Medical Research Centre (St. Petersburg) from January 2023 March 2024. eligibility criteria BMI values 25–40 kg/m² glycated hemoglobin level not exceeding 9.5%. Results. showed serum positively correlated severity assessed based findings. Furthermore, significantly decreased as result therapy GLP-1RAs SGLT-2 Conclusion. These correlation data suggest could be used promising diagnostic marker T2D, both stage evaluation when considering outcomes ongoing therapy.

Язык: Английский

---

Prevotella copri-produced 5-aminopentanoic acid promotes pediatric metabolic dysfunction-associated steatotic liver disease

Hepatobiliary & pancreatic diseases international, Год журнала: 2025, Номер unknown

Опубликована: Фев. 1, 2025

Язык: Английский

---

Association between metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction subtypes and risk of colorectal cancer: A Prospective Cohort Study

Clinics and Research in Hepatology and Gastroenterology, Год журнала: 2025, Номер unknown, С. 102573 - 102573

Опубликована: Март 1, 2025

Язык: Английский

---

National Protect Liver Day 2025 in China: Integrating Traditional Chinese Medicine and Western Medicine to Reverse Liver Cirrhosis

Liver Research, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

Язык: Английский

---

Metabolic Dysfunction-Associated Steatotic Liver Disease Induced by Microplastics: An Endpoint in the Liver–Eye Axis

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(7), С. 2837 - 2837

Опубликована: Март 21, 2025

There is a significant, rather than just anecdotal, connection between the liver and eyes. This evident in noticeable cases such as jaundice, where sclera has yellow tint. But this can be seen through even more subtle indicators, molecules known hepatokines. relationship not merely anecdotal; some studies, it referred to “liver–eye axis”. Ubiquitous environmental contaminants, microplastics (MPs), enter bloodstream human body conjunctival sac, nasolacrimal duct, upper respiratory tract mucosa. Once absorbed, these substances accumulate various organs cause harm. Toxic from surface of eye lead local oxidative damage by inducing apoptosis corneal cells, irregularly shaped microparticles exacerbate effect. Even other toxicants ocular may absorbed into distributed throughout body. Environmental toxicology presents challenge because many pollutants same route that used certain medications. Previous research indicated accumulation MPs play major role development chronic disease humans. It crucial investigate whether buildup potential fibrosis, or simply consequence conditions cirrhosis portal hypertension.

Язык: Английский

---